Effect of Light-bed Photodynamic Therapy (PDT) on Cancer - Phase 2
Phase 2
- Conditions
- CancerCancer - Any cancer
- Registration Number
- ACTRN12624000349549
- Lead Sponsor
- ational Institute of Integrative Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
adults diagnosed with cancer;
baseline CTC count before LBT treatment:: 5-20 CTC/ml
suitable/ eligible for HBOT therapy (as per standard guidelines for HBOT, an accredited clinical service; e.g. no sinus blockage)
Exclusion Criteria
planned other treatment including surgery within 1 week
Porphyria
Claustrophobia, anxiety
Not able to provide consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CTC count (number of CTC per ml) by cytology[Circulating Tumour Cell (CTC) enrichment from 10ml of blood using the ISET (Isolation by Size of Tumour Cells) methodology by Rarecells Diagnostics, France before (within 2-4 weeks of) treatment, 1 week after and 3 months after lightbed treatment]
- Secondary Outcome Measures
Name Time Method Safety & tolerability[by our standard research side effects & tolerability questionnaire immediately after treatment and at follow-up at 1 week]